Articles published by Cortexyme, Inc.

Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022

July 27, 2022

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

July 27, 2022

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

June 21, 2022

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Appoints June Bray to its Board of Directors

June 13, 2022

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Appoints Dr. Philip Low to Its Board of Directors

May 20, 2022

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Successfully Completes Acquisition of Novosteo

May 20, 2022

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases

May 12, 2022

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Announces Agreement to Acquire Novosteo

May 10, 2022

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population

March 21, 2022

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors

March 15, 2022

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme to Present New GAIN Trial Data at AD/PD 2022

March 14, 2022

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones

February 01, 2022

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Announces Change in Executive Leadership Team

February 01, 2022

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application

January 26, 2022

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th

November 23, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021

November 11, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th

November 04, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression

October 26, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021

September 27, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588

September 08, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th

September 07, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit

August 25, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme to Present at Annual Biomarkers for Alzheimer’s Disease Summit

August 18, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Provides Business Update and Reports Second Quarter 2021 Results

August 09, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th

August 04, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021

July 26, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection

July 23, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme to Present New Data at AAIC 2021

July 22, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021

July 21, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Cortexyme to Host Symposium at AAIC 2021

July 19, 2021

From Cortexyme, Inc.

Via Business Wire

Tickers CRTX

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.